DailyIQ
|
Sector:HealthcareAll sectors
Last updated 7 minutes ago

ABCL·AbCellera Biologics Inc.

$.
-. (-.%)
After Hours
High
$7.39
Open
$7.28
Market Cap
2.08B
52W High
$8.44
Low
$6.60
P. Close
$6.79
P/E
-
52W Low
$2.75
Fwd P/E
-9.44
DailyIQ Est.
$11.15
Technical Score (1D)
82
BUY
News Sentiment
51
MIXED
AbCellera’s second‑quarter 2026 financial results will be announced on August 5, 2026, with an earnings call at 2 p.m. PT, setting the stage for the next 1–10 trading days. The upcoming report is expected to confirm or revise guidance on antibody pipeline progress, a key driver for short‑term valuation. A momentum‑pick article highlights a recent price rally and a strong earnings trajectory, indicating that traders are already pricing in near‑term upside. Benchmark Securities’ upgrade to Buy with an $11 target reflects confidence that upcoming data releases will validate the antibody platform, reinforcing the bullish sentiment that may sustain the rally. The upgrade also signals that analysts anticipate the Q2 earnings to confirm pipeline milestones, a critical catalyst for the next trading days. The appointment of Dr. Lynn Seely to the board adds clinical and commercial expertise, potentially accelerating decision‑making on candidate prioritization and partnership negotiations. Together, these developments create a near‑term catalyst window where any positive earnings or pipeline data could lift the stock further, while negative surprises could trigger a pullback. Traders should watch the Q2 earnings call for guidance updates, the release of any Phase 2 data for ABCL‑635, and any joint milestones from the Jazz collaboration that could materialize in the coming weeks. Monitoring regulatory filings and partnership progress will also be crucial, as they could confirm the company’s strategic direction and validate the recent analyst upgrades.
Earnings Summary
AbCellera Biologics Inc., a Canadian biotechnology firm headquartered in Vancouver, specializes in antibody discovery and development, targeting unmet medical needs in the U.S. market and collaborating with industry leaders such as Eli Lilly, Viking Global Investors, ArrowMark Partners, and Biogen; its pipeline includes ABCL635 for metabolic disorders and ABCL575 for autoimmune conditions, positioning it within the biotechnology sector. In the most recent quarters, AbCellera reported EPS of –$0.12 in Q4 2024, beating the –$0.151 estimate, and –$0.15 in Q1 2025, missing the –$0.142 estimate; Q2 2025 EPS improved to –$0.12 versus –$0.163, a beat, while Q3 2025 EPS of –$0.19 missed the –$0.162 estimate; the Q4 2025 EPS of –$0.03 surpassed the –$0.177 estimate, and revenue surged from $5.10 M in Q4 2024 to $44.85 M in Q4 2025, reflecting a dramatic increase in commercial activity; the company’s earnings trend shows a gradual narrowing of losses and a significant revenue jump in the fourth quarter, suggesting progress in its pipeline commercialization. Historically, AbCellera has oscillated between negative EPS and modest revenue growth, but the recent Q4 2025 revenue spike and EPS beat indicate a potential turning point; the company’s pattern of incremental gains aligns with its focus on antibody discovery and partnership development. Recent news highlights Benchmark Securities’ upgrade to a Buy rating with a $11 target, citing progress in the antibody pipeline, and the appointment of Dr. Lynn Seely to the board, whose oncology and strategic experience is expected to accelerate partnership negotiations; these developments may enhance investor confidence and open new revenue streams. Investors should watch for upcoming clinical data releases for ABCL635 and ABCL575, any new licensing or partnership announcements, and the impact of the board’s strategic guidance on pipeline prioritization, as these factors will influence the company’s next earnings cycle.

EPS

EstBeatMiss
$-0.21$-0.16$-0.11$-0.06$-0.01Q4'24Q1'25Q2'25Q3'25Q4'25Q2'26
QtrEstActual+/−
Q2'26$-0.17 - -
Q4'25$-0.18$-0.03+83.1%
Q3'25$-0.16$-0.19-17.3%
Q2'25$-0.16$-0.12+26.5%
Q1'25$-0.14$-0.15-5.3%
Q4'24$-0.15$-0.12+20.8%

Revenue

EstBeatMiss
$-2M$11M$25M$38M$51MQ4'24Q1'25Q2'25Q3'25Q4'25Q2'26
QtrEstActual+/−
Q2'26$8M - -
Q4'25$6M$45M+625.1%
Q3'25 - $9M -
Q2'25 - $17M -
Q1'25 - $4M -
Q4'24 - $5M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ABCL Stock Snapshot

ABCL is currently trading at $6.88, giving AbCellera Biologics Inc. a market cap of 2.08B. Today's range spans $6.60–$7.39, with shares opening at $7.28 and moving up $0.09 (1.3%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 51/100.

Over the past year ABCL has traded between $2.75 and $8.44 - the current price is +150.1% off the 52-week low and -18.5% from the high. 17 analysts cover the stock with a Buy consensus and a mean 12-month target of $10.50 (range $7.00–$13.00), implying upside of +52.7%.

At 2.08B in Healthcare market cap, ABCL isn't on every institutional screen - yet. The current setup (BUY, 82/100, neutral sentiment at 51/100, price $6.88 (in the upper portion of its 52-week range)) is the kind of data profile that changes that. When small-cap Healthcare names show bullish technicals with aligned news sentiment, discovery buying and fundamental upgrades can accelerate the move beyond what the signal alone predicts. Range: $2.75–$8.44.

The combination of a BUY technical signal (82/100) and neutral news sentiment (51/100) in a small-cap like ABCL (2.08B, Healthcare) creates the kind of setup that shows up in small-cap momentum screens used by growth-oriented funds. At $6.88 (in the upper portion of its 52-week range in $2.75–$8.44), the stock is not yet crowded — which means the entry risk-reward is better than it will be if the technical and sentiment setup persists and attracts wider institutional attention.